We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Futura Medical Plc | FUM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 16.50 | 12:57:05 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 17.30 | 16.48 | 17.30 | 16.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 30/1/2025 22:36 by mdi The warning signals were there to see and again I didn’t see any real overt ‘boasting&rsquIts also quite apparent Sanofi are still also very keen now to try get Cialis OTC in the USA. MDI - 04 Nov 2024 - 15:11:24 - 21850 of 21998 The real question is how much and how long are they willing to risk keep spending on NFL TV ads for Eroxon. Trying to build acceptance of an alcohol and water gel brand built around a placebo medical device clearance: That any competitor if inclined and believes it is a real sustainable product can launch a similar non medicated hydroalcoholic gel in the category via the 510k pathway. Especially after what we saw with the sales declines in the UK and Belgium. Is today them now admitting the poor consumer feedback in the US already following a similar path. And literally the hard reality is to keep long term repeat purchasers they need a more ‘intense&rsquo ‘Launches of new categories, such as erectile dysfunction cream Eroxon, may drag on profitability until they gain consumer acceptance’ Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isnt due to the hype cycle, but rather the placebo cycle. Here's a startling fact: between 80% and 90% of new product launches fail, according to multiple studies including Harvard Business Review. Each year, more than 30,000 new products hit the market, from companies large and small, and year after year, history is littered with dead carcasses Research at the Ehrenberg-Bass Institute shows new product launches can be a risky undertaking for brand owners. Investigating 83,719 new product introductions over an eight-year period, the research finds around one in four new products failed to survive one year after launch. This failure rate increased to around 40% two years after launch. Why Most Product Launches fail |
Posted at 30/1/2025 08:01 by mdi All very predictable. How long before partners give up on all the expensive TV advertising of a placebo gel and then just walk away like happened with all Futura’s previous products?Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. A company may have testimonials, five-star reviews and sales growth, but all of that could be due to the consumers beliefs about the product, rather than the product itself This belief results in the ˜placebo effect’ which is why rigorous clinical trials compare a product against a placebo (which looks like the product but has no active ingredient of its own, e.g., a sugar pill). This is necessary to prove any real effects of the product beyond placebo |
Posted at 19/1/2025 23:23 by mdi bandflex it was already confirmed in the 2023 Futura results that H2 sales in UK and Belgium were collapsing and were less then H1. So revenues of £3.1M in 2023 equated to only £1.4M for H2 compared to £1.7M in H1. The staggering of launches in different countries makes it look like revenue is increasing but it also masks the underlying sales declines in countries they had already launched and as sales then start to decline it’s reflected in the increasing numbers of people realising its just made of alcohol and water and reporting it doesn’t work and its just a placebo scam.Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isnâ€â&bdquo |
Posted at 29/11/2024 18:33 by beanol Response from Investor relations."Many thanks for reaching out. In regard to your query, this trade was an intra fund trade and requires no TR1 as there was no overall movement in the investors holding" Mate ie MDF your comment is a replying to was ill considered and frankly daft. Indeed 80% of your posts are in that ven. Please get with the leit motif of BBs ie its a forum to exchange info and ideas. Yes there will be posters who ramp and who relegate sticks but try to exercise a bit of human savoirbfaire in your posts whatever you ñr personal holding i |
Posted at 29/11/2024 17:31 by petroc Had the fraudster MDI reached out to investor relations at FUM regarding the big trade, he would have been told this:"Many thanks for reaching out. In regard to your query, this trade was an intra fund trade and requires no TR1 as there was no overall movement in the investors holding." |
Posted at 23/11/2024 14:22 by mdi ‘placebo response rates tend to increase with transdermal gel’Placebo response to manual therapy: something out of nothing Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. A company may have testimonials, five-star reviews and sales growth, but all of that could be due to the consumers beliefs about the product, rather than the product itself This belief results in the ‘placeb |
Posted at 01/11/2024 12:11 by mdi ‘Launches of new categories, such as erectile dysfunction cream Eroxon, may drag on profitability until they gain consumer acceptance’Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. A company may have testimonials, five-star reviews and sales growth, but all of that could be due to the consumers beliefs about the product, rather than the product itself This belief results in the ‘placebo effect’ which is why rigorous clinical trials compare a product against a placebo (which looks like the product but has no active ingredient of its own, e.g., a sugar pill). This is necessary to prove any real effects of the product beyond placebo |
Posted at 29/10/2024 17:52 by mdi Wellness Investors: Beware The Placebo TrapWhats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. A company may have testimonials, five-star reviews and sales growth, but all of that could be due to the consumers beliefs about the product, rather than the product itself’ This belief results in the ˜placebo effect’ which is why rigorous clinical trials compare a product against a placebo (which looks like the product but has no active ingredient of its own, e.g., a sugar pill). This is necessary to prove any real effects of the product beyond placebo And the regulators are biting to show that they aren’t just barking. In March 2023, federal regulators began investigating social media platforms for their potential role in advertising misleading products, including ones with fraudulent health claims. Then, in April 2023, federal regulators sent warning letters to 670 wellness companies related to health claims without proof |
Posted at 26/10/2024 23:10 by mdi Amazon US star rating for Eroxon is worse then UK. Its looking even worse in terms of percentage star ratings then the 50% oral placebo effect reported in some of the double blind randomised controlled ED studies. How long before just like in the Uk they give up on the expensive US TV advertising and same as happened in uk sales start to decline? Or the TV advertising leads to unwanted attention and FTC/legal questions about the implied ‘clinically proven’ claims that Eroxon is making but cannot be substantiated with any double blind placebo controlled study?Customer reviews 1.7 out of 5 stars1.7 out of 5 ‘the placebo effect in RCT of iPDE5 for ED occurs at a rate as high as 50%’ According to reviews. You would be better off buying cheaper Zeebo pills on Amazon which based on the ˜clinically proven’ Eroxon marketing claims being allowed. Zeebo could also now claim to the FTC and FDA they are also ‘clinically proven’ to the same level of marketing standards currently being allowed be used by Eroxon. 4.3 out of 5 stars Wellness Investors: Beware The Placebo Trap Whats the problem with placebos? Placebo effects tend to wear off, and when they do, your customers will drop off. This forces tremendous spending on acquisition since it can cost five times as much to acquire new customers than keep current ones. Since repeat customers generate more than half of the revenue for a majority of businesses, pretty packaging of a placebo will likely struggle to sustain sales. Perhaps the boom and bust commonly seen with wellness brands isn’t due to the hype cycle, but rather the placebo cycle. A company may have testimonials, five-star reviews and sales growth, but all of that could be due to the consumers beliefs about the product, rather than the product itself’ This belief results in the ˜placebo effect’ which is why rigorous clinical trials compare a product against a placebo (which looks like the product but has no active ingredient of its own, e.g., a sugar pill). This is necessary to prove any real effects of the product beyond placebo And the regulators are biting to show that they aren’t just barking. In March 2023, federal regulators began investigating social media platforms for their potential role in advertising misleading products, including ones with fraudulent health claims. Then, in April 2023, federal regulators sent warning letters to 670 wellness companies related to health claims without proof |
Posted at 18/4/2023 16:44 by lbo Plenty of big sells! looking forward to the fundraising! LOLTherefore, from June 2022 it had roughly 13 months of cash runway it's fair to say the end of the cash runway is in sight FOR EVERY BUYER THERE MUST BE A SELLER Jay: What I meant was, where did the shares you purchased come from? They didn’t come out of thin air. Someone had to sell them to you. The market has two types of investors: individuals like you and me, and institutional investors such as pension funds, mutual funds and hedge funds. Do you believe the seller was more likely another individual investor like you? Or was the seller more likely one of those institutional investors? Haden: I would guess the seller was another individual investor. Jay: That’s incorrect. Since today institutional investors do about 90 percent of all trading, there’s about a 90 percent chance the seller was an institution. Since we now agree the underlying reason you bought the stock was that you believed it would outperform the market, we can also agree the underlying reason the institutional investor sold the stock was that it believed the stock would underperform the market. If that were not the case, it would have continued to hold the stock. Correct? Haden: I guess so. Jay: Okay. You believed it would outperform the market, and the institutional investor believed it would underperform. How many of you can be correct? Haden: Just one. Jay: If you’re re being perfectly honest with yourself, who do you believe had more knowledge about the company”you or the institutional investor? Haden: I’d have to say the institutional investor. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
